Every strategy deck should have one uncomfortable slide

Every strategy deck should have one uncomfortable slide:

👉 What’s our Achilles heel?

Not the usual clichés… “margin pressure” or “competition.”

I mean the existential risks:

• What event could take us out of the game long enough that we never recover?

• Where are we dangerously over-reliant? One product, one site, one client, one market?

Pharma has brutal reminders:

• Ranbaxy (2013–2014): FDA bans crippled its U.S. business. Within a year, it was acquired by Sun Pharma. Achilles heel: regulatory trust.

• Actavis (2000s–2012): Overextended with acquisitions and debt until Watson swallowed it. Achilles heel: over-leverage.

• Schering-Plough (2009): Narrow portfolio and looming cliffs forced a merger with Merck. Achilles heel: concentration risk.

• Pharmacia (early 2000s): Integration failures and pipeline weakness led to Pfizer acquisition. Achilles heel: pipeline fragility.

• Genentech (2009): Reliance on blockbusters and Roche’s structure meant full takeover. Achilles heel: ownership vulnerability.

• Celgene (2019): Dependence on Revlimid made it a target for BMS. Achilles heel: single-product reliance.

As Taleb reminds us in Antifragile, black swans don’t send calendar invites. You can’t predict which heel gets hit, but you can design resilience:

• Diversification- beyond one molecule, market, or client.

• Redundancy- back-up sites, suppliers, leadership.

• Optionality- the freedom to pivot when markets or regulators shift.

Fragile companies play “what if.”

Anti-fragile companies play “even if.”

The hardest boardroom question is also the most liberating one:

👉 Even if our Achilles heel gets hit, do we survive, adapt, and come out stronger?

🔔 Follow for insights 

♻️ Share if you find it interesting